We have an unwavering commitment to improving care for patients with serious medical conditions through ongoing clinical development programs.
To learn more about clinical trials that are currently underway and to find out if a study is enrolling patients in your area or with your condition, please visit www.clinicaltrials.gov.
The results of certain applicable Jazz clinical trials are also available at www.clinicaltrials.gov.
As part of Jazz’s commitment to putting patients first, we are providing plain language summaries for certain clinical trials. These plain language summaries provide clinical trial results in an easy-to-understand format so all patients can obtain more information on the study results. Learn more about our study results.
IMforte is a Phase 3 clinical trial evaluating lurbinectedin in combination with the PD-L1 inhibitor atezolizumab as a first-line maintenance treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). The trial, conducted in collaboration with F. Hoffmann-La Roche Ltd (Roche), will measure the progression-free survival and overall survival benefits of lurbinectedin in combination with atezolizumab administered in combination compared to atezolizumab alone. The primary objective of IMforte is to determine the ability of this new combination to improve outcomes for patients with ES-SCLC, compared with standard-of-care first-line maintenance as measured by progression-free survival and overall survival.
This is a Phase 2/3 Clinical Study evaluating the investigational medication JZP458 for the treatment for pediatric and adult patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginases. For more information, and to find out if a site is enrolling patients near you, please contact JZP458201@jazzpharma.com.
JZP150 is a small molecule fatty acid amide hydrolase (FAAH) inhibitor in clinical development. Monarch is a Phase 2 clinical study evaluating the investigational medicine, JZP150, for the treatment of adult patients with posttraumatic stress disorder (PTSD). The purpose of this study is to learn more about the safety and tolerability of JZP150, as well as to evaluate whether JZP150 will improve symptoms of PTSD. For more information, and to find out if a site is enrolling patients near you, please visit https://www.monarchstudyptsd.com/ or clinicaltrials.gov (NCT05178316).
This is a phase 2b clinical study evaluating the investigational medication suvecaltamide (JZP385) for the treatment of adult patients with moderate to severe essential tremor. The purpose of this study is to learn more about the safety and tolerability of the study medication, as well as to evaluate whether the study medication will improve disability associated with tremor. The study is enrolling people (age 18-80 years) who have been diagnosed with ET according to the Movement Disorder Society Consensus Statement on the Classification of Tremors from the Task Force on Tremor of the International Parkinson’s and Movement Disorder Society. Patients must also have moderate to severe disability associated with their tremor as defined by the Tremor Research Group Essential Tremor Rating Scale [TETRAS] and clinician’s assessment. For more information, and to find out if a site is enrolling patients near you, please visit www.EveresTstudy.com or Clinical Trials.gov (NCT05122650).
This is a patient-centric, virtual study examining the impact of transitioning from Xyrem to Xywav in a real-world setting. The purpose of the study is to observe the dosing practices during the transition, and learn more about the safety and tolerability of the medication, as well as overall treatment satisfaction. Self-reported information is collected through web-based questionnaires. For more details about this study or to enroll, please visit www.tenorstudy.com.
This page is for U.S. residents only. By clicking on this page, you confirm you are a U.S. resident.
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.